July 20, 2021
Article
The 22F and 33F serotypes, which are associated with high rates of invasiveness and antibiotic resistance, are unique to the pneumococcal 15-valent conjugate vaccine.
June 29, 2021
Although it is the most common hospital-acquired infection, hospitals are not required to report non-ventilator-associated hospital-acquired pneumonia to the CDC National Healthcare Safety Network.
June 23, 2021
The investigators said that although pneumococcal vaccines were known to reduce severe cases of childhood pneumonia, no studies from Asia had measured their efficacy until now.
June 15, 2021
June 09, 2021
The vaccine includes all 13 serotypes in the Prevnar 13 vaccine, as well as conjugates for 7 additional serotypes associated with high case-fatality rates, antibiotic resistance, and meningitis.
April 26, 2021
The antibiotic fights both resistant enterococcus, streptococcus, and staphylococcus bacteria via a unique mechanism of action, which causes resistance to develop at a very slow pace.
April 07, 2021
Empiric anti-MRSA therapy is an area of opportunity for antimicrobial stewardship in the treatment of CAP.
January 18, 2021
Macrophages could be critical treatment targets because they could be infected by SARS-CoV-2 and can contribute to spreading the infection through the lung.
January 13, 2021
The FDA will review a Biologics License Application for V114, Merck’s investigational 15-valent pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease.
December 08, 2020
The objective of the study was to develop a method for de-escalation of intravenous (IV) vancomycin in patients receiving vancomycin with at least 1 other antibiotic appropriate for the treatment of community-acquired pneumonia (CAP).
